Located in the heart of vibrant Mexico City, our clinic offers world-class fertility solutions. With initial online consultations available, we invite you to explore your options from the comfort of your home. Our team will be happy to assist you in planning your journey and provide you with the exceptional care you deserve on your path to parenthood.
Contact us today to schedule your initial consultation and take the first step towards making your family a reality.
Leave us your details and we will contact you to schedule an online consultation.
We personalize the process for every one of our patients, offering all-inclusive packages, medical, and emotional support to make your experience as smooth as possible
Our cutting-edge technology has not only created new families, but has also made it possible for them to decide how and when.
We offer an innovative concept of reproductive assistance with or without a partner to plan the next generation.
We monitor the health of various embryos and choose only the healthiest for implantation, helping ensure a smooth pregnancy.
We use the latest methods available to choose the highest quality spermatozoa, giving your child the absolute best chances for success.
With over 30 years of experience between our fertility biologists, our state of the art procedures are matched with the expertise to use them effectively.
Schedule a consultation to learn more, and our team of specialists will be happy to answer all your questions.
We use the most patient-friendly techniques to ensure your comfort while achieving the best possible results
We design unique and fully personalized treatments for couples facing fertility challenges, single parents, same-sex couples wanting to start a family, and those wishing to postpone parenthood..
It is a procedure in which the fertilization and formation/creation/incubation of embryos are carried out outside the uterus, to later implant them and achieve pregnancy. The IVF process can vary slightly for each patient, but there are 5 basic steps;
Hormonal medication application
Egg Retrieval
Fertilization the eggs
Genetic testing of the embryos
Embryo transfer to the uterus
Previously, a fertility study must be performed to make the diagnosis and determine if IVF is the appropriate treatment.
Once these studies have been carried out, the woman must begin hormonal treatment for ovarian stimulation, in order to obtain the eggs that will later be fertilized in the laboratory and prepare the uterus for the implantation of the embryo.
It is ideal for women or couples who do not want to undergo hormonal stimulation to obtain more eggs or women who have undergone multiple fertilization processes and the medication produces adverse effects or they cannot produce more than one or two eggs after stimulation.
IVF creates embryos in the laboratory with an egg from the female and a sperm from the male. The embryos generated are finally transferred into the mother’s uterus, where a normal pregnancy develops.
Gentle IVF is a variation of conventional IVF, with minimal ovarian stimulation. The rest of the steps of this technique are identical to those of conventional IVF.
It is ideal for patients who wish to use lower doses of hormones during treatment without decreasing the likelihood of pregnancy.
Gentle IVF is a lighter treatment during ovarian stimulation, administering oral medications and lower doses of injectable medications. This reduces side effects, promotes tolerance to treatment and reduces the risk of ovarian hyperstimulation.
This option provides fewer injections, shorter stimulation time and, in general, greater comfort for the patient.
This technique allows us to extract an average of 3 quality eggs, which will be fertilized in the laboratory and transferred or vitrified with the intention of accumulating them in some cases (embryo pooling).
Gentle IVF is a treatment plan that is tailored to the patient’s unique needs:
It is a treatment for those women who are looking for a less invasive alternative to traditional IVF.
Total Price: $10,200 USD
Nowadays, forming a family between women and both participating in the process is possible through the ROPA method (Reception of Couple’s Eggs). The method consists of one of them contributing the eggs and the couple receiving the embryos, bringing the pregnancy to term. Therefore, they are both biological mothers.
We establish a reproductive assessment of the couple, evaluating the age, ovarian reserve, quality of the eggs and the uterus, in order to achieve the greatest possibility of success.
In the ROPA method, one of the women’s eggs are inseminated with donor sperm through IVF.
Egg donation is currently one of the most used and effective assisted reproduction treatments, allowing pregnancy in women with compromised ovarian reserve in quality or quantity.
CdelaF has an altruistic egg donation program that is very demanding in its selection criteria. The donors are women <30 years old in very good health. In addition to a thorough psychological, medical and gynecological evaluation, genetic tests are performed to detect the main genetic alterations.
At CdelaF we treat our donors with the utmost care, respect and extreme confidentiality and we monitor their safety at all times.
Egg donation is not usually the first choice treatment when a woman or couple goes to a fertility clinic. However, there are cases in which egg donation is considered the best or only option to achieve a healthy pregnancy.
Depending on the origin of the eggs, there are mainly two types of egg donation:
In an egg donation treatment, it is the egg donor who undergoes the ovarian stimulation process. Once the eggs are mature, follicular aspiration is scheduled and the mature oocytes are extracted to be fertilized in the IVF laboratory. After fertilization, the embryos are transferred to the recipient’s uterus, previously prepared for implantation.
Egg vitrification consists of the ultra-rapid freezing of oocytes instead of using a traditional freezing method so that the eggs are not damaged and preserve maternity until the patient indicates or desires it.
A vitrification process (ultra-rapid freezing) is carried out that protects cells from damage caused by the formation of ice crystals.
The success rate of IVF with vitrified eggs is similar to that obtained with eggs in the best phase.
In addition, the CdelaF team is a pioneer in the research of new techniques and equipment for automatic egg vitrification. Dr. Rodríguez Purata presented the first newborn through the use of GAVI at the Annual Congress of the American Society for Assisted Reproduction (ASRM).
It is an assisted reproduction technique that allows sperm to be cryopreserved for long periods of time without losing their fertilizing capacity.
Semen cryopreservation is currently the only alternative to preserve the reproductive potential of men undergoing potentially sterilizing treatments.
It is necessary to perform blood tests prior to semen freezing to determine the infectious risk (HIV, hepatitis and syphilis serology).
It is conditioned to:
An in-depth evaluation of both women is carried out to establish a treatment strategy that leads to the best results.
Women without a partner or with an unstable partner can face fertility alone through artificial insemination or In Vitro Fertilization with donor sperm or even through embryo donation.
The egg of one of the women is inseminated with donor sperm. The selection of the sperm donor is made by the specialist taking into account the phenotype (race, complexion, hair color and type, eye color, etc.) and blood group compatibility.
Total Price: $5,600 USD
Today, genetics offers great support to reproductive medicine, providing different tests depending on the reproductive stage in which the couple is.
Once IVF has been performed, Preimplantation Genetic Diagnosis (PGD or PGD) studies genetic health.
Normally, to perform a PGD there must be a prior indication from a specialist.
The PGD study must be performed on embryos generated in an IVF cycle. It is important to have an adequate number of embryos to find the embryos with the greatest implantation potential.
To perform PGD in CdelaF, the embryos are cultured strictly until the blastocyst stage, which is reached on day 5-6 after fertilization. At that time, the Embryonic Biopsy of the external layer also called trophectoderm, which will give rise to the placenta, is performed.
Embryo Biopsy is the technique that allows a small hole to be made in the trophectoderm of the embryo and 4-5 cells to be aspirated. Since these cells will give rise to the placenta, it does not affect the development of the embryo. Once the biopsy is performed, the embryo is vitrified or transferred into the uterus once the result of the analysis is known.
PGD consists of analyzing the genetic status of the embryo. Biopsied samples of all embryos are studied in a genetics laboratory. Once the study is completed, the laboratory provides a report indicating the embryos that have the greatest implantation potential.
Thanks to Preimplantation Genetic Diagnosis we can prevent better-known diseases such as Down syndrome, but also many of the so-called rare diseases, and even some types of hereditary cancer.
Total Price: $3,850 USD
We integrate all the specialties to treat maternity in all its phases from planning and how to treat or find different alternatives to be a mother.
Low responders are one of the current challenges of assisted reproduction techniques. It is estimated that between 9-14% of patients who undergo an IVF cycle have a low response.
This pathology is increasing in recent years due to delayed motherhood. Unfortunately, it is well established that low response is associated with high cancellation rates and lower rates of chance of pregnancy relative to patients with a normal response.
One of the main causes of low ovarian reserve is age, although it is true that biological age does not always correspond to ovarian age. There are women who are born with a smaller number of oocytes and others who develop many follicles in each menstrual cycle.
At CdelaF we apply personalized and differentiating stimulation strategies, always with the aim of selecting the optimal cycle that ensures the best egg, which entails great knowledge of the variability of menstrual cycles and a medium-term strategy. Slowly but surely.
Endometriosis is a disease that generally causes two types of problems: pain or infertility. Before we dive in, let’s focus on the female reproductive anatomy, which can be divided into 3 key organs:
To understand endometriosis, it is helpful to understand the lining of the walls of the uterus, the endometrium, and the cells it is made of (known as “endometrial cells”). Endometrial cells are special: they grow abnormally fast in the presence of estrogen. When they grow, they create a thick inner endometrial lining of the uterus and this helps ensure that an embryo can implant into its wall. An embryo needs good implantation to ensure that it receives nourishment and can develop into a fetus. When endometrial cells escape, that is endometriosis.
Endometrial cells are useful when they are contained in the uterus, but when they escape from the uterus, they wreak havoc. When these cells implant and establish themselves in other organs, they cause inflammation and local damage. In fact, this is endometriosis.
The most common places where the endometrium usually adheres are:
The main symptoms of endometriosis are related to pelvic discomfort and infertility.
Other symptoms that can determine endometriosis are:
If some of these symptoms are present in your body, at CdelaF we offer you the appropriate diagnosis to know if you suffer from this disease, as well as the timely treatment for endometriosis.
The presence of endometriosis can make it difficult for a woman to conceive. Specifically, endometriosis can interfere with reproductive components and functions such as:
By implanting and “eating” on the ovaries, endometriosis can reduce egg count. Antral follicle counts (AFC) and anti-Müllerian hormone (AMH) levels are two commonly used indicators of ovarian reserve, and recent studies have suggested that patients with endometriosis have reduced ovarian reserve, even before they are done. attempts to eliminate endometriosis.
Surgery to remove endometriosis in the ovaries can also further reduce ovarian reserve. Endometriosis adheres closely to normal ovarian tissue and some of the normal ovarian tissue is inevitably removed during removal of endometriosis from the ovary. For patients with good ovarian reserve, these changes may not affect the likelihood of having a successful pregnancy, but for patients with already low reserves, particularly those who will need IVF, surgery may have a significant negative impact.
Additionally, endometriosis can create a microenvironment that can worsen egg quality. A meta-analysis of 22 studies and 6,760 IVF patients showed that patients with endometriosis have lower fertilization rates and lower implantation rates per embryo than other patients (in this case, those with blocked tubes). Additionally, a small study shows that embryos created from eggs from donors with endometriosis are much less likely to implant than embryos created from eggs from donors without endometriosis.
Endometriosis and related scarring around the fallopian tubes can create blockages or abnormal functions that prevent the egg or embryo from moving through the tube or the sperm from moving up. This may prevent the sperm from fertilizing the egg or, if fertilization occurs, prevent movement of the resulting embryo through the tube, increasing the risk of a tubal (ectopic) pregnancy. In a recent study of more than 14,000 women, women with endometriosis were 2.7 times more likely to have an ectopic pregnancy than women without endometriosis. Although the absolute numbers are small, ectopic pregnancies can be very dangerous.
When endometriosis cells colonize other organs, they cause inflammation. Since the uterus is part of a larger reproductive ecosystem, when other organs become inflamed, so does the uterus. This can affect the ability of the uterus to allow an embryo to implant and receive nourishment. An interesting design study showed that recipients of embryos from donors with endometriosis are at least 20% less likely to have embryo implants than recipients of embryos from donors who did not have endometriosis.
Regardless of where endometriosis exists, it causes inflammation, and if sperm swim near the region of inflammation, their motility (ability to swim) and function may be affected. The percentage of sperm with DNA damage doubles after exposure to pelvic fluid from patients with endometriosis compared to sperm exposed to pelvic fluid from women without endometriosis.
Endometriosis affects approximately 1 in 10 women during their reproductive years. Among patients with infertility, endometriosis is at least twice as common, affecting 20 to 70% of women with infertility, according to the study.
However, the true prevalence of endometriosis can be difficult to determine because there is generally little effectiveness in identifying it in a timely manner, if it is detected at all. Most women with endometriosis report that they were consulted at least five times before receiving a diagnosis with an average delay of 10 years. This is because gynecologists and patients rule out or “normalize” menstrual cramps and other nonspecific gastrointestinal symptoms that may be a sign of endometriosis: 75% of the women studied were first seen by a general gynecologist.
Personalized ovarian stimulation treatments with antral enhancement may slightly increase the number of eggs, but substantially improve the quality of the eggs recovered. In addition to personalizing the protocols, monitoring and the ability to adapt to the evolution of the cycle of the patient with endometriosis is essential for the success of the treatment.
In other cases, the patient with endometriosis needs to resort to minor surgeries to improve uterine anatomy and functionality and try to ensure the implantation of the embryo as much as possible.
The different assisted reproduction techniques help to achieve pregnancy, however, an individualized strategy is necessary from the moment the disease is diagnosed and that lasts beyond achieving pregnancy. Our goal is to treat the disease to limit its degree of impact in terms of fertility, taking advantage of the different possibilities that reproductive medicine offers us in case we do not achieve a pregnancy naturally.
Genetic infertility is caused by some alteration in the DNA sequence of the woman or man who is trying to have a child. Depending on the type of genetic anomaly, it is possible to differentiate between:
As an introduction, let’s start by differentiating what chromosomes are and what genes are. As for the chromosomes, you can imagine that they are as if they were structures where there is information, like bookshelves where the books are, which in this case would be the genes. That is, there are many genes on a chromosome. Therefore, sometimes there is an alteration of only one gene, other times there is an alteration of the entire chromosome, and therefore of all the genes on that chromosome.
Sometimes, future parents are not aware that they are carriers of some genetic alteration until they begin to have difficulties achieving a pregnancy. The CdelaF specialized genetics unit aims to diagnose and prevent chromosomal anomalies and genetic diseases in the embryo before it is implanted, avoiding repeated abortions, implantation problems and possible genetic diseases.
Repeated failures in IVF treatments generate great frustration for both patients and assisted reproduction professionals. There are several factors that can lead to the failure or failure of the IVF technique. The main ones are the lack of eggs, the failure of fertilization of the eggs and therefore the absence of embryo creation, implantation failure or the difficulty of carrying the pregnancy to term.
CdelaF specialists will be able to explain to you the causes of implantation failures and why the final goal of IVF treatment is not reached: a healthy baby at home.
It is well known that the success of an implementation depends on:
In recent years, special attention is being paid to the implementation window. This is the period of time in which the uterus is most receptive to the embryo. Thanks to innovative genomic and proteomic studies, we can analyze the implantation window of each woman and determine with greater effectiveness and efficiency the moment of embryo transfer to increase the probability of implantation and therefore pregnancy.
Hysteroscopy is one of the most important diagnostic tests in patients with repeated implantation failure in order to rule out intracavitary pathologies that could have gone unnoticed with conventional diagnostic means (2D and 3D transvaginal ultrasound, hysterosalpingography and hysterosonosalpingography, nuclear magnetic resonance). Hysteroscopy allows visual confirmation of the state of the cervical canal and uterine cavity.
It is very important to identify and rule out as much as possible in order to determine the possibilities of intervention in patients with repeated IVF failures.
At CdelaF we offer you a comprehensive treatment evaluating:
Infertility can have a very diverse origin: 30% is due to female causes, another 30% to male causes and 20% has mixed causes, that is, both members of the couple present alterations.
The remaining 20%, however, has an unknown origin. This means that, after having done all the usual diagnostic tests, the results are normal and it is unknown what may be altering the female or male reproductive system to prevent pregnancy.
Since we are talking about infertility of unknown origin, it is difficult to explain the real reasons why a couple does not achieve pregnancy.
However, experience in assisted reproduction treatments has detected some alterations that could be the causes of this difficulty in conceiving. We explain them below:
CdelaF is an expert in the treatment of infertility of unknown origin. After several attempts with assisted reproduction techniques, it is very possible that there is a multifactorial cause that makes pregnancy difficult. At CdelaF we believe that infertility always has a reason. Given this diagnosis, we focus our efforts on investigating the causes using all available diagnostic techniques until we discover the reason.
CdelaF is one of the few fertility clinics that studies, diagnoses and treats the immunological factors involved in the reproduction process. Immune system disorders and autoimmune diseases can cause infertility in both men and women. These disorders are difficult to diagnose, but approximately 20% of cases of infertility of unknown origin are due to some type of immune disorder.
Infertility of immunological origin has different ways of manifesting itself: it can destroy the gametes themselves, prevent embryo implantation or even cause repeated spontaneous abortions.
Some of the types of immunological infertility that we treat are:
It is believed that male factor infertility impacts between 30 and 50% of all cases in which couples have problems getting pregnant. There may be a variety of underlying factors that contribute to male factor infertility, and the reality is that some may herald a deep and troubling problem with a man’s health. Therefore, male factor infertility may be a symptom of something more concerning that needs to be addressed.
But it is important to know that although many cases can be resolved using the fertilization technique called ICSI (Intracytoplasmic Sperm Injection), often less invasive and less expensive approaches can give the same result.
To properly characterize the underlying problem and consider alternative approaches to an IVF cycle, men should be seen by an experienced fertility urologist trained in male anatomy (Reproductive Urologist or Andrologist). The reality is that male factor infertility is often detected by reproductive endocrinologists, who are doctors who specialize in fertility, but at the end of the day they are gynecologists.
At CdelaF we help with a number of crucial issues including:
Premature ovarian failure, previously known as premature ovarian failure, is defined as the disappearance of ovarian activity at an age before 40 years. This means that the ovaries stop working before reaching menopause. Therefore, the woman does not ovulate and her blood levels of estrogen and progesterone decrease.
Typically, the cause of this ovarian failure is unknown, although there is an increased risk when there is a history of ovarian failure in immediate family members.
Unfortunately, in 90% of cases of ovarian failure, the exact cause is unknown. Of the causes that we do know, the most common are:
The symptoms of ovarian failure are usually similar to those that a woman experiences when she goes through menopause, since these symptoms are due to a lack of estrogen.
The absence of menstruation (amenorrhea) is the most striking factor for a young woman and is the main reason for consultation.
Specifically, we speak of premature ovarian failure when a woman under 40 years of age presents an absence of menstruation, very low levels of estrogen, and gonadotropin levels above 40 mIU/mL.
Other symptoms associated with low estrogen levels are the following:
The first warning sign in women is the absence of menstruation or scant and irregular menstrual periods. Therefore, to find out the cause, it is best to go to a gynecological consultation. The doctor takes a medical history along with a physical and gynecological examination.
To confirm the presence of premature ovarian failure, a blood test is performed to evaluate the hormones FSH and estradiol. A high FSH and low estradiol establishes evidence of ovarian failure. These determinations will be repeated on more than one occasion to confirm the diagnosis.
In the reproductive context, what is most effective is doing an IVF cycle. At CdelaF we offer specific ovarian stimulation treatments designed and proven for patients with premature ovarian failure.
And for exceptional cases in which IVF does not generate a response, we offer for the first time in Mexico the AMTO method (mechanical activation of ovarian tissue), which is recommended in patients < 35 years old and with FSH > 20. The AMTO method consists of a surgical procedure to activate the functionality of the ovary, a method established in Europe.
Faced with the shocking news of cancer, new lives seem to take a backseat. However, it is very important to consider preserving fertility to have the possibility of becoming a mother in the future.
There is no age for this disease. In children and people of reproductive age, the fertility preservation technique has great value.
Many people who have overcome cancer discover that they cannot conceive, either because of the doses of radiation they have received or because of the effects of some drugs used in chemotherapy. In the past, not much attention was usually paid to this dimension of treatment, but as more and more patients survive the disease, interest in so-called Oncofertility has been increasing.
Therefore, if you have been diagnosed with cancer and have to postpone motherhood, we give you the possibility of preserving your ability to have children so that, in the future, you do not have to give up being a mother.
At CdelaF we provide free fertility preservation treatments for all cancer patients diagnosed and treated at our center.
In our centers we offer different methods to do so:
After hormonal treatment so that your ovaries produce a greater number of eggs, the oocytes are extracted and cryopreserved (a technique that consists of preserving cells or tissues at a temperature between -80° and -196°).
It consists of obtaining fragments of ovarian tissue through laparoscopy to cryopreserve them. Laparoscopy is a minimally invasive surgery technique in which the abdomen is accessed through very small incisions.
It consists of extracting the oocytes, fertilizing them in vitro with the partner’s or donor’s sperm and cryopreserving the embryos through vitrification.
Once you decide it’s time:
The uterus is, along with the ovaries, the most important organ in a woman’s reproductive system. The uterus is capable of responding to the sexual hormones that intervene in the menstrual cycle and is also responsible for maintaining the pregnancy of the baby for 9 months.
Alterations in both the shape and function of the uterus are a cause of female infertility. Depending on the severity or type of alteration, there will be complications in achieving pregnancy or maintaining it, to the point that the woman is forced to give up her dream of being a mother. At CdelaF we help so that this never happens.
In the treatment of uterine problems, the diagnosis process requires an in-depth study of it. Due to its morphology and its changing nature throughout the menstrual cycle, the uterus can hide defects depending on the time at which the examination is performed.
In the initial proliferative phase (post-menstruation) we can assess the existence of sub-endometrial pathology while in the late proliferative phase (pre-ovulatory) we explore endometrial morphology. The luteal (post-ovulatory) phase is the best time to evaluate myometrial adenomyosic pathology.
At CdelaF we study cases of uterine factor in depth and we have extensive experience and training to correct those problems that could be impacting fertility.
Polycystic ovary syndrome (PCOS or PCOS) is the most common endocrinopathy in women of reproductive age, with an incidence of 6 to 21% of the population, representing the most common form of chronic anovulation.
Its symptoms are so varied that a diagnosis may not even be reached until problems achieving pregnancy are detected and assisted reproduction treatment is necessary.
For this reason, the diagnosis of PCOS has always been a controversial topic and subject to constant modifications, making it difficult to establish which diagnostic tests are the most appropriate and what their hierarchy should be.
With polycystic ovary syndrome, more androgens are produced than usual and the menstrual cycle is not regulated correctly. In the ovary, the follicles do not release the eggs because they do not mature and cysts are produced. Due to this absence of maturation and release of the egg, women with polycystic ovary syndrome have affected fertility.
This syndrome is a problem of metabolic origin that should not be confused with polycystic ovaries, which is only an ultrasonographic characteristic that may or may not be present in patients with PCOS and that does not have to be accompanied by infertility.
The most common clinical manifestations suffered by women with polycystic ovary syndrome are the following:
The key to success in infertility treatments in patients with PCOS is to carefully study all the symptoms of each patient and direct said treatment individually, taking into account the particular hormonal values at different times of the menstrual cycle.
When a woman is born, she has around 400,000 eggs in her ovaries, of which only about 400 will mature into mature eggs, preparing to be fertilized. This is the so-called ovarian reserve, which decreases and loses quality over the years. Although there are no techniques to improve the quality of these eggs, we can know how many a woman has, and with this information we can better understand the chances of pregnancy after assisted reproduction treatment.
Pathologies such as polycystic ovary syndrome, endometriosis, etc., are treatable in most cases, but there are other circumstances such as age that require a different strategy. The aging of the egg is a determining factor in ovular quality; the aging of the egg makes fertilization difficult or can even cause repeated abortions.
There are different strategies to overcome the presence of poor quality eggs. These strategies are personalized, since poor quality in younger patients is not the same as in older patients. In these cases we focus the effort on defining and selecting the best cycles to perform oocyte aspiration. Furthermore, it is essential to propose a stimulation strategy that leads us to obtain the best oocyte.
Hello, I'm Dr. Enrique Cervantes, and I completed my specialization in Gynecology and Obstetrics at the Tecnológico de Monterrey. I have a subspecialty that I studied in New York, at Mount Sinai Hospital, under the guidance of Dr. Benjamin Sandler, in Reproductive Endocrinology and Infertility, which is Reproductive Medicine. I had the opportunity to be part of the medical and research team in the USA for several years, which allowed me to participate and present my scientific studies at American congresses on several occasions. I started my private practice in Mexico 6 years ago, advising patients with infertility and assisted reproduction.Three years ago, I founded CdelaM, and from there arose the need to take the clinic to the next level, so we decided to start a new, more innovative project called CdelaF.
Hello, I'm Dr. Maitane Alonso, a graduate of the Gynecology and Obstetrics specialty program at Centro Médico ABC. I pursued advanced training in Infertility and Assisted Reproduction Techniques at Hospital Ángeles Lomas, under the guidance of Dr. Alberto Kably, a pioneer in reproductive medicine in our country. I also gained formative experience in Reproductive Medicine at the Dexeus Institute in Barcelona, one of the most renowned reproduction centers worldwide. I've had the opportunity to author and co-author several articles in the field of reproduction, and I am part of the editorial team of the JBRA journal. Additionally, I am the head of the endocrinology course for the third year of the Gynecology and Obstetrics specialty program at Centro Médico ABC. Currently, I am part of the medical team at CdelaF and CdelaM.
Hello, I'm María José Gómez, a graduate in Biology and Master in Bioethics from the University of Barcelona. I have a specialization in Embryology from the Spanish Society of Embryology and the European Society of Human Reproduction and Embryology. I began my journey in assisted human reproduction in 1992 at the Dexeus University Institute, where I remained until 2003. Subsequently, I took the lead on a laboratory project in Tuscany, Italy, undoubtedly one of the best experiences up to that point. In 2007, I returned to the Dexeus Institute to assume the responsibility of the In Vitro Fertilization Laboratory. Currently, I have joined CdelaF's team as the laboratory head, a new, innovative, and high-tech project.
Based in City of Mexico, we deliver state of the art fertility care at a 70% discount compared to US prices. Find out how we can make your family a reality today.